Novo Nordisk shares fall despite improved outlook as Wegovy sales disappoint

Novo Nordisk (NYSE:NVO) raised its full-year guidance after reporting continued demand for its weight-loss treatments, but weaker-than-expected sales of its oral Wegovy medication and disappointing clinical trial results for a next-generati